

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivilsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018
 Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2025

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 31/12/2025	3 months ended 30/09/2025	3 months ended 31/12/2024	9 months ended 31/12/2025	9 months ended 31/12/2024	12 months ended 31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
I	Revenue from operations	19,717.81	18,588.27	15,951.33	56,954.02	46,337.54	66,151.49
II	Other income	410.96	97.85	93.76	847.65	805.70	945.53
III	Total Revenue (I + II)	20,128.77	18,686.12	16,045.09	57,801.67	47,143.24	67,097.02
IV	Expenses:						
	Cost of materials consumed	11,431.40	13,151.03	11,865.35	36,972.93	32,536.03	46,327.71
	Purchases of Stock-in-Trade	3,148.00	1,839.16	1,454.93	7,636.80	2,762.14	3,854.64
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	548.34	(536.84)	(1,272.57)	233.76	(207.14)	(245.44)
	Employee benefits expense	691.06	674.55	553.58	1,995.40	1,619.30	2,303.92
	Finance costs	7.96	7.56	28.03	36.65	58.58	61.93
	Depreciation and amortization expense	300.25	286.18	218.13	837.93	598.34	873.94
	Other expenses	2,218.94	2,272.42	1,871.09	6,218.01	5,403.43	7,819.79
	Total expenses (IV)	18,345.95	17,694.06	14,718.54	53,931.48	42,770.68	60,996.49
V	Profit / (Loss) before exceptional and items and tax (III - IV)	1,782.82	992.06	1,326.55	3,870.19	4,372.56	6,100.53
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V - VI)	1,782.82	992.06	1,326.55	3,870.19	4,372.56	6,100.53
VIII	Tax expenses:						
	(1) Current tax	493.00	280.00	318.00	1,022.00	983.00	1,467.00
	(2) Deferred tax	(59.66)	(49.19)	(25.76)	(92.66)	(105.93)	(165.22)
	(3) Income tax of earlier years	4.38	-	-	4.38	6.00	63.56
	Total Tax expenses (VIII)	437.72	230.81	292.24	933.72	883.07	1,365.34
IX	Profit/(Loss) after Tax (VII-VIII)	1,345.10	761.25	1,034.31	2,936.47	3,489.49	4,735.19
X	Other Comprehensive Income (net of Tax)						
	(i) Items that will not be reclassified to profit or loss	45.55	8.37	0.77	47.85	(11.97)	(1.70)
	(ii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (net of Tax) (X)	45.55	8.37	0.77	47.85	(11.97)	(1.70)
XI	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	1,390.65	769.62	1,035.08	2,984.32	3,477.52	4,733.49
	Paid up Equity Share Capital (Face value Rs. 5/- each) (Refer note no. 4)	5,011.20	5,011.20	2,505.60	5,011.20	2,505.60	2,505.60
	Other Equity (excluding revaluation reserves)	-	-	-	-	-	30,096.88
XII	Earnings per equity share (For respective periods) (In Rs.) (Refer note no. 4)						
	(1) Basic	1.34	0.76	1.03	2.93	3.48	4.72
	(2) Diluted	1.34	0.76	1.03	2.93	3.48	4.72

See accompanying notes to the financial results



 ANUH PHARMA LTD.
 MUMBAI

Notes:-

1. These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act 2013 ('the Act) read with the Companies (Indian Accounting Standards) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).

2. These unaudited financial results for the quarter and nine months ended December 31, 2025 were reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on 06th February, 2026 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the Statutory Auditors of the Company.

3. Other Financial indicators

(Rs. in Lakhs)

Particulars	3 months ended 31/12/2025	3 months ended 30/09/2025	3 months ended 31/12/2024	9 months ended 31/12/2025	9 months ended 31/12/2024	12 months ended 31/03/2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
EBITDA	2,091.04	1,285.80	1,572.71	4,744.78	5,029.48	7,036.40
% of EBITDA Margin	10.60	6.92	9.86	8.33	10.85	10.64
EBITDA (Adjusted to Forex (gain) / loss and Mark to Market (gain) / loss on Investment in Mutual funds)	2,402.53	1,729.82	1,617.78	5,275.50	4,669.46	6,957.15
% of Adjusted EBITDA Margin	12.18	9.31	10.14	9.26	10.08	10.52

4. During the quarter ended September 30, 2025 the shareholders of the company have approved, through the postal ballot, the issuance of the bonus shares, in the proportion of 1:1 i.e. 1(one) bonus equity share of Rs 5 each for every 1(one) fully paid up equity share held on as on the record date. Accordingly, the company has allotted 5,01,12,000 as a bonus shares on 16th July, 2025 by utilization of General reserves. All the shares and per share information in the financial results reflect the effect of the bonus share issuance.

5. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising 4 labour codes (the New Labour Codes), effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has ascertained its estimated obligations under the New Labour Codes. Accordingly, the Company has recognised incremental estimated obligations aggregating to Rs.48.31 Lakhs under "Employee benefit expense on account of employees past services, based on actuarial valuation and best estimate in accordance with Ind AS 19- 'Employee Benefits' and consistent with guidance provided by the Institute of Chartered Accountants of India. The Company continues to monitor the finalisation of Central and State Rules and clarifications from the Government on other aspects of the New Labour Codes and would provide appropriate accounting effect on the basis of such developments, as needed.

6. The Company does not have any subsidiary/associate/joint ventures as on 31st December 2025.

7. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

8. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Ltd.



Ritesh Shah
Joint Managing Director
(DIN: 02496729)



Place : Mumbai

Date : 06th February, 2026

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

TO THE BOARD OF DIRECTORS

Anuh Pharma Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Anuh Pharma Limited** (the "Company") for the quarter ended 31st December, 2025 and year to date results for the period from 1st April, 2025 to 31st December, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)**

D. J. Thakkar



**PLACE: Mumbai
DATE: 6th February, 2025**

**DILIP J THAKKAR
PARTNER
MEMBERSHIP NO. 005369
UDIN: 26005369PZROVE9497**